The Managing Directors and Principals of Frankel Group have over 100 years of pharmaceutical and life science industry experience, and together with the team of seasoned Frankel Group Senior Consultants, Consultants, Associates and Analysts bring expertise from not only the supplier side of the healthcare industry but also in-depth experience from the academia, payer, provider and investment sectors of the industry as well.

Sidnee C. Pinho

Frankel Group Experience

Sidnee has been with Frankel Group since 1997, during which time she has worked on an array of project types that span the pharmaceutical/biotechnology value chain, from efficiency of discovery efforts and clinical development planning, through strategic marketing and sales planning, as well as franchise development in various therapeutic categories. Her disease expertise is broad as well, including gastroenterology, infectious disease, rheumatology, oncology, and cardiovascular conditions.

Some of the most recent projects that she has managed include the development of a clinical development plan and target product profile for a bone-marrow derived stem cell product for the treatment of acute myocardial infarction, in addition to a study of orphan indications and the potential to leverage Proof-of-Concept (POC) trials to garner formal FDA approval. Sidnee was also part of the team that developed Frankel Group's CELESTIAL MATRIXSM , a customer segmentation and prioritization tool that uses statistical regression to determine the potential of each individual customer account.

In addition to her client work, Sidnee serves as the firm's Director of Operations and has responsibility for overseeing the firm's strategic and operational initiatives. These include Frankel Group's strategic planning process, as well as staff optimization (e.g., capacity planning, training, mentoring, recruiting, professional development, etc.).

Pre-Frankel Group Experience

Prior to joining Frankel Group, Sidnee worked as an equity research associate for Deutsche Banc Alex Brown covering the biotechnology market. Prior to DB, she was with Booz-Allen & Hamilton in their Communications, Media & Technology Practice where she was a strategy consultant in the areas of benchmarking, market modeling, and due diligence. In addition, she has worked in the Marketing Services and International Finance divisions of Pfizer, Inc, and led a student team that built and launched a telescope for NASA and the University of Pennsylvania Physics Department in 1995 (technologies included GPS directional analysis and CCD imaging).

Education

Sidnee has earned a BAS in Systems Engineering from The School of Engineering at the University of Pennsylvania, a BSE in Finance and Multinational Management from The Wharton School, and an MBA in Finance and Marketing from NYU/Stern.

Doug B. Pfaff

Frankel Group Experience

Doug joined Frankel Group in 2005. His projects have spanned numerous therapeutic areas including cardiology, CNS, hematology, immunology, inflammation, metabolics, oncology, rheumatology, and women's health. He has also served a range of client types, from big pharma to small biotech, to other related sectors such as private equity, contract sales and medical devices.

Doug's work has covered an array of project types, including: (1) corporate strategy: setting corporate vision to extend the business model beyond the status quo and developing the business plan to support the vision, (2) compound lifecycle planning: prioritizing and sequencing opportunities based on clinical, commercial and strategic criteria, (3) due diligence: developing recommendations on potential licensing and acquisition deals, (4) war-gaming: preparing and facilitating sessions for a product team to enhance their understanding of their competitors' likely strategies and their best response to these strategies, (5) process document development: setting best practices for key processes such as TPP development, risk assessment and portfolio analysis, and (6) technology strategy: working with client's scientists to determine what level of investment, if any, was appropriate for each emerging technology of interest.

Pre-Frankel Group Experience

Prior to joining Frankel Group, Doug was a Case Team Leader at Bain & Company, a strategy consulting firm. While at Bain, Doug worked in a wide range of areas including market assessment, asset/company due diligence and valuation, sales force optimization, strategic prioritization of business units, and implementation project management. Prior to Bain, Doug worked as the head of engineering for the surgical products division of Getinge/Castle, Inc.

Education

Doug holds a Masters of Business Administration with honors from Columbia Business School, and a Bachelors of Science Summa Cum Laude in Engineering from Duke University.

Benjamin N. Rymzo

Frankel Group Experience

Ben first joined Frankel Group in 1999, and rejoined the firm in 2007. His experience spans a range of therapeutic areas including infectious disease, respiratory disease, dermatology, inflammatory disease, cardiovascular disease, diabetes and metabolic disorders, as well as technology platform experience in cell therapy and drug delivery. Recent projects have included an analysis of global growth opportunities in infectious disease to establish an investment strategy for a global biopharmaceutical company, franchise development strategy for an established biotechnology product, and a vaccine market entry strategy for a biotechnology company. Prior engagements have also spanned market assessments, target product profile identification, and competitive strategy.

Pre-Frankel Group Experience

Prior to joining Frankel Group, Ben was with the Strategy & Operations Group of Deloitte Consulting, in their Health Care & Life Sciences Practice. While there, his engagements included growth strategy, M&A strategy, new product development and roll-out planning, market assessment, and competitive strategy.

Education

Ben holds a BA from the College of Arts & Sciences at Cornell University, and an MBA in Finance from New York University Stern School of Business.

Dave Konciak

Frankel Group Experience

Dave joined Frankel Group in 2008 where his recent project experience has included asset due diligence for both financial and strategic buyers, licensing strategy development for a global biopharmaceutical company, and a franchise creation strategy for a niche specialty pharmaceutical company. Prior engagements have crossed the entire value chain and range from indication sequencing/target product profile development for early stage assets to a lifecycle management strategy for a $3.5 billion compound. Dave's experience spans a variety of therapeutic areas including oncology, inflammation, metabolics, pulmonology, cardiology, and pain management.

Pre-Frankel Group Experience

Prior to joining Frankel Group, Dave was a Manager at Deloitte Consulting where he led consulting engagements for global pharmaceutical, medical device, and contract R&D companies. Specific areas of focus included product portfolio analysis, business development strategy, R&D optimization, corporate governance, and organizational development. Before Deloitte, Dave worked for Taratec Development Corporation, a boutique life sciences consulting firm, where he guided the launch of two new offerings, built the firm's marketing department, and helped secure a round of Series A venture capital. Additionally, Dave has experience as an independent consultant leading a team in conducting an in-depth licensing assessment for an early stage oncology therapy for a $2 billion specialty pharmaceutical company.

Education

Dave holds a BS Magna Cum Laude from Muhlenberg College and an MBA in Finance and Healthcare from the Wharton School of Business.

Robert J. Pogulis, Ph.D.

Frankel Group Experience

Rob joined Frankel Group in 2006. Since joining the firm, he has worked on a variety of engagements including market/opportunity assessment, product development and commercialization strategy, franchise development, life cycle management, channel strategy, business development screening, technology assessment, R&D collaboration planning and investment due diligence. Therapeutic areas of focus have spanned Oncology, Immune/Inflammatory Disease, Infectious Disease, CNS, Urology, Dermatology, Endocrinology, Blood/Coagulation Disorders, and Vascular Disease. Rob has also worked in the biomarker and diagnostics arena across several of these therapeutic areas, as well as in the CRO space.

Pre-Frankel Group Experience

Prior to joining Frankel Group, Rob was Director of Business Development and Strategic Planning at Transgenomic Inc., a genomics company providing products/services to support translational research, molecular diagnostics and personalized medicine. Rob previously worked in equity research at RBC Capital Markets, with companies under coverage including major US-based pharmaceutical companies, and life sciences research tools providers.
Rob began his professional career as a Research Fellow in the Department of Immunology at the Mayo Clinic, and subsequently joined Wyeth Vaccines as a Sr. Research Scientist. His research pursuits have included regulation of gene expression, gene therapy, molecular and cellular immunology, novel therapeutic strategies for multiple sclerosis, vaccine discovery, and methods development.

Education

Rob holds a Ph.D. in Biological Chemistry from the University of Michigan and a B.S. in Biochemistry from the University of Minnesota.